HCW Biologics (HCWB) EBIAT (2020 - 2025)
HCW Biologics (HCWB) has disclosed EBIAT for 6 consecutive years, with -$4.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT fell 16.71% year-over-year to -$4.6 million, compared with a TTM value of -$12.1 million through Sep 2025, up 67.72%, and an annual FY2024 reading of -$30.0 million, down 20.12% over the prior year.
- EBIAT was -$4.6 million for Q3 2025 at HCW Biologics, down from -$1.9 million in the prior quarter.
- Across five years, EBIAT topped out at -$1.9 million in Q2 2025 and bottomed at -$15.3 million in Q2 2024.
- Average EBIAT over 5 years is -$4.8 million, with a median of -$3.9 million recorded in 2022.
- The sharpest move saw EBIAT tumbled 254.99% in 2024, then soared 87.38% in 2025.
- Year by year, EBIAT stood at -$3.2 million in 2021, then crashed by 70.75% to -$5.4 million in 2022, then tumbled by 97.1% to -$10.7 million in 2023, then soared by 68.42% to -$3.4 million in 2024, then tumbled by 35.01% to -$4.6 million in 2025.
- Business Quant data shows EBIAT for HCWB at -$4.6 million in Q3 2025, -$1.9 million in Q2 2025, and -$2.2 million in Q1 2025.